1. Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents

3. Introduction/Overview

4. VKA-Associated Bleeding: Results From the RADOA Registry

5. Reversal Agents for VKA-Associated Anticoagulation

6. Management of Urgent Anticoagulation Reversal: 4F-PCC vs FFP

7. Anticoagulation Reversal Strategies for Platelet Aggregation Inhibitors

8. Anticoagulation Reversal With Vitamin K

9. FFP for Anticoagulation Reversal

10. Protocols Needed to Improve Treatment of Patients in Need of Anticoagulation Reversal

11. Recent Anticoagulation Reversal Clinical Trials

12. 4F-PCC vs FFP: A Systematic Review and Meta-Analysis, Mortality Results

13. 4F-PCC vs FFP: A Systematic Review and Meta-Analysis, Additional Outcomes

14. 4F-PCC vs Plasma for Rapid VKA Reversal in Patients Needing Urgent Surgical or Invasive Interventions: Primary Endpoint Results

15. NOACs Compared With Warfarin for Bleeding Endpoints

16. NOAC Anticoagulation Reversal Agents

17. Scientific Rationale for Use of 4F-PCC in Bleeding Anticoagulated Patients: Results From a Phase 3b Trial

18. Results of a Skin-Punch Biopsy Study on Edoxaban Bleeding and Reversal by 4F-PCC

19. Updated European Heart Rhythm Association Practical Guide: Management of NOAC-Associated Bleeding

20. RADOA Registry: Patient Recruitment

21. RADOA Registry: Reversal of NOACs, VKAs - Preliminary Findings and Unresolved Issues

22. 4F-PCC for Warfarin-Associated Intracranial Hemorrhage

23. What Do Guidelines Recommend for Anticoagulation Reversal?

24. Summary and Conclusions

25. Abbreviations

26. Abbreviations (cont)